Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A High-Throughput Assay for DNA Replication Inhibitors Based upon Multivariate Analysis of Yeast Growth Kinetics.

Ngo M, Wechter N, Tsai E, Shun TY, Gough A, Schurdak ME, Schwacha A, Vogt A.

SLAS Discov. 2019 Jul;24(6):669-681. doi: 10.1177/2472555219829740. Epub 2019 Feb 25.

PMID:
30802412
2.

Integrating Analysis of Cellular Heterogeneity in High-Content Dose-Response Studies.

Gough A, Shun TY, Taylor DL, Schurdak M.

Methods Mol Biol. 2018;1745:25-46. doi: 10.1007/978-1-4939-7680-5_2.

PMID:
29476461
3.

Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.

Jia S, Miedel MT, Ngo M, Hessenius R, Chen N, Wang P, Bahreini A, Li Z, Ding Z, Shun TY, Zuckerman DM, Taylor DL, Puhalla SL, Lee AV, Oesterreich S, Stern AM.

Oncology. 2018;94(3):176-189. doi: 10.1159/000485510. Epub 2018 Jan 6.

4.

High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines.

Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Grandis JR.

Methods Mol Biol. 2018;1683:229-244. doi: 10.1007/978-1-4939-7357-6_14. Erratum in: Methods Mol Biol. 2018;1683:E1.

5.

Biologically Relevant Heterogeneity: Metrics and Practical Insights.

Gough A, Stern AM, Maier J, Lezon T, Shun TY, Chennubhotla C, Schurdak ME, Haney SA, Taylor DL.

SLAS Discov. 2017 Mar;22(3):213-237. doi: 10.1177/2472555216682725. Epub 2017 Jan 6. Review.

6.

The Microphysiology Systems Database for Analyzing and Modeling Compound Interactions with Human and Animal Organ Models.

Gough A, Vernetti L, Bergenthal L, Shun TY, Taylor DL.

Appl In Vitro Toxicol. 2016 Jun 1;2(2):103-117. doi: 10.1089/aivt.2016.0011.

7.

A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens.

Gough A, Shun TY, Lansing Taylor D, Schurdak M.

Methods. 2016 Mar 1;96:12-26. doi: 10.1016/j.ymeth.2015.10.007. Epub 2015 Nov 4.

8.

HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell lines.

Johnston PA, Sen M, Hua Y, Camarco DP, Shun TY, Lazo JS, Wilson GM, Resnick LO, LaPorte MG, Wipf P, Huryn DM, Grandis JR.

Assay Drug Dev Technol. 2015 Sep;13(7):356-76. doi: 10.1089/adt.2015.663.

9.

A human liver microphysiology platform for investigating physiology, drug safety, and disease models.

Vernetti LA, Senutovitch N, Boltz R, DeBiasio R, Shun TY, Gough A, Taylor DL.

Exp Biol Med (Maywood). 2016 Jan;241(1):101-14. doi: 10.1177/1535370215592121. Epub 2015 Jul 22.

10.
11.

Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery.

Gough AH, Chen N, Shun TY, Lezon TR, Boltz RC, Reese CE, Wagner J, Vernetti LA, Grandis JR, Lee AV, Stern AM, Schurdak ME, Taylor DL.

PLoS One. 2014 Jul 18;9(7):e102678. doi: 10.1371/journal.pone.0102678. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0120468.

12.

In vitro platforms for evaluating liver toxicity.

Bale SS, Vernetti L, Senutovitch N, Jindal R, Hegde M, Gough A, McCarty WJ, Bakan A, Bhushan A, Shun TY, Golberg I, DeBiasio R, Usta BO, Taylor DL, Yarmush ML.

Exp Biol Med (Maywood). 2014 Sep;239(9):1180-1191. doi: 10.1177/1535370214531872. Epub 2014 Apr 24. Review.

13.

Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans.

Bhushan A, Senutovitch N, Bale SS, McCarty WJ, Hegde M, Jindal R, Golberg I, Berk Usta O, Yarmush ML, Vernetti L, Gough A, Bakan A, Shun TY, DeBiasio R, Lansing Taylor D.

Stem Cell Res Ther. 2013;4 Suppl 1:S16. doi: 10.1186/scrt377. Epub 2013 Dec 20. Review.

14.

High-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.

Johnston PA, Sen M, Hua Y, Camarco D, Shun TY, Lazo JS, Grandis JR.

Assay Drug Dev Technol. 2014 Jan-Feb;12(1):55-79. doi: 10.1089/adt.2013.524. Epub 2013 Oct 15.

15.

Alkylation sensitivity screens reveal a conserved cross-species functionome.

Svilar D, Dyavaiah M, Brown AR, Tang JB, Li J, McDonald PR, Shun TY, Braganza A, Wang XH, Maniar S, St Croix CM, Lazo JS, Pollack IF, Begley TJ, Sobol RW.

Mol Cancer Res. 2012 Dec;10(12):1580-96. doi: 10.1158/1541-7786.MCR-12-0168. Epub 2012 Oct 4.

16.

Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus.

Johnston PA, Shinde SN, Hua Y, Shun TY, Lazo JS, Day BW.

Assay Drug Dev Technol. 2012 Oct;10(5):432-56. doi: 10.1089/adt.2012.456. Epub 2012 Jul 25.

17.

Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity.

Sharlow ER, Mustata Wilson G, Close D, Leimgruber S, Tandon M, Reed RB, Shun TY, Wang QJ, Wipf P, Lazo JS.

PLoS One. 2011;6(10):e25134. doi: 10.1371/journal.pone.0025134. Epub 2011 Oct 5.

18.

Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.

Kitchens CA, McDonald PR, Shun TY, Pollack IF, Lazo JS.

J Pharmacol Exp Ther. 2011 Dec;339(3):851-8. doi: 10.1124/jpet.111.184879. Epub 2011 Aug 31.

19.

Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.

Shun TY, Lazo JS, Sharlow ER, Johnston PA.

J Biomol Screen. 2011 Jan;16(1):1-14. doi: 10.1177/1087057110389039. Epub 2010 Dec 15.

PMID:
21160066
20.

Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin ╬▒1-antitrypsin Z.

Gosai SJ, Kwak JH, Luke CJ, Long OS, King DE, Kovatch KJ, Johnston PA, Shun TY, Lazo JS, Perlmutter DH, Silverman GA, Pak SC.

PLoS One. 2010 Nov 12;5(11):e15460. doi: 10.1371/journal.pone.0015460.

21.

Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Dudgeon DD, Shinde SN, Shun TY, Lazo JS, Strock CJ, Giuliano KA, Taylor DL, Johnston PA, Johnston PA.

Assay Drug Dev Technol. 2010 Aug;8(4):437-58. doi: 10.1089/adt.2010.0281.

22.

Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.

Dudgeon DD, Shinde S, Hua Y, Shun TY, Lazo JS, Strock CJ, Giuliano KA, Taylor DL, Johnston PA, Johnston PA.

J Biomol Screen. 2010 Aug;15(7):766-82. doi: 10.1177/1087057110375304. Epub 2010 Jul 16.

PMID:
20639499
23.

Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments.

Soares KM, Blackmon N, Shun TY, Shinde SN, Takyi HK, Wipf P, Lazo JS, Johnston PA.

Assay Drug Dev Technol. 2010 Apr;8(2):152-74. doi: 10.1089/adt.2009.0247.

24.

Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.

Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, Pollack IF.

Neurosurg Focus. 2010 Jan;28(1):E4. doi: 10.3171/2009.10.FOCUS09210.

PMID:
20043719
25.

Identification of survival genes in human glioblastoma cells by small interfering RNA screening.

Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, Lazo JS.

Mol Pharmacol. 2009 Dec;76(6):1246-55. doi: 10.1124/mol.109.058024. Epub 2009 Sep 25.

26.

Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets.

Thaker NG, McDonald PR, Zhang F, Kitchens CA, Shun TY, Pollack IF, Lazo JS.

J Neurosci Methods. 2010 Jan 15;185(2):204-12. doi: 10.1016/j.jneumeth.2009.09.023. Epub 2009 Sep 25.

PMID:
19782703
27.

Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

Johnston PA, Foster CA, Tierno MB, Shun TY, Shinde SN, Paquette WD, Brummond KM, Wipf P, Lazo JS.

Assay Drug Dev Technol. 2009 Jun;7(3):250-65. doi: 10.1089/adt.2008.186.

28.

Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents.

Johnston PA, Soares KM, Shinde SN, Foster CA, Shun TY, Takyi HK, Wipf P, Lazo JS.

Assay Drug Dev Technol. 2008 Aug;6(4):505-18. doi: 10.1089/adt.2008.151.

29.

HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus.

Johnston PA, Phillips J, Shun TY, Shinde S, Lazo JS, Huryn DM, Myers MC, Ratnikov BI, Smith JW, Su Y, Dahl R, Cosford ND, Shiryaev SA, Strongin AY.

Assay Drug Dev Technol. 2007 Dec;5(6):737-50. doi: 10.1089/adt.2007.101.

PMID:
18181690
30.

Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.

Sharlow ER, Leimgruber S, Shun TY, Lazo JS.

Assay Drug Dev Technol. 2007 Dec;5(6):723-35. doi: 10.1089/adt.2007.102.

PMID:
18181689
32.

Development and optimization of high-throughput in vitro protein phosphatase screening assays.

Tierno MB, Johnston PA, Foster C, Skoko JJ, Shinde SN, Shun TY, Lazo JS.

Nat Protoc. 2007;2(5):1134-44.

PMID:
17546004

Supplemental Content

Support Center